ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE
October 20-21, 1999
SLIDES
Planning Clinical Development in Catheter Related Bacteremia, Ray Zhu, PhD, Biostatistics, Rhone-Poulenc Rorer
Isaam
Raad, MD, Chief, Section of Infection Control, Professor of Medicine, MD Anderson Cancer Center, Houston, TX
LEVAQUIN®
(levofloxacin), Tablets or Injection for PRSP and PISP in Community-Acquired Pneumonia, Edward Cox, M.D., Medical
Officer/DSPIDP
LEVAQUINâ
(levofloxacin) Graham Burton, MD, Global Clinical Research and Regulatory Affairs
Reporting Rates for Serious Cardiac Dysrhythmias Among
Fluoroquinolones, Azithromycin, Clarithromycin, and Cefuroxime, Allen Brinker, MD, MS, Office of Postmarking Drug Risk Assessment
(OPDRA)
Moxifloxacin, Clinical Efficacy, Andrea Meyerhoff MD MSc
DTMH, Division of Special Pathogens, US FDA
A Review of the Safety of Moxifloxacin
Hydrochloride, Leonard Sacks MD, Medical Officer/DSPIDP (HTM)
(PPT)
NDA 21-085 Avelox (moxifloxacin hydrochloride tablets) Bayer Pharmaceutical Division, Bayer Corporation
ppt html